PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 22.72

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.32M

Analyst Target

USD 30.11
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
SOLV Solventum Corp.

N/A

USD 10.78B
DOCS Doximity Inc

N/A

USD 7.70B
WEAV Weave Communications Inc

N/A

USD 0.89B
AMWL American Well Corp

N/A

USD 0.14B
MPLN MultiPlan Corporation

N/A

USD 0.12B
OWLT Owlet Inc

N/A

USD 0.07B
TDOC Teladoc Inc

N/A

N/A
FOXO FOXO Technologies Inc.

N/A

N/A
EVH Evolent Health Inc

N/A

N/A
VEEV Veeva Systems Inc Class A

N/A

N/A

ETFs Containing PHR

W311:XETRA HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.18 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.86% 30% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.86% 30% F 25% F
Trailing 12 Months  
Capital Gain 21.63% 40% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.63% 40% F 62% D
Trailing 5 Years  
Capital Gain -6.58% 50% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.58% 50% F 42% F
Average Annual (5 Year Horizon)  
Capital Gain 13.28% N/A N/A 75% C
Dividend Return 13.28% N/A N/A 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 68.16% N/A N/A 12% F
Risk Adjusted Return 19.48% N/A N/A 38% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector